Vivani Medical Strengthens Executive Leadership With Appointment Of Anthony Baldor As Chief Financial Officer

Vivani Medical, Inc., a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants, has announced the appointment of Anthony Baldor as its new Chief Financial Officer. He takes over the role from Brigid A. Makes, who is retiring from the company to concentrate on board responsibilities and personal pursuits following a successful tenure marked by meaningful contributions to Vivani’s growth. Makes will continue to provide guidance in an advisory capacity to ensure a smooth transition.

Vivani Chief Executive Officer Adam Mendelsohn, PhD, said in a statement, “Anthony’s deep expertise in financial strategy will be instrumental as Vivani advances its pipeline and scales its operations. We are excited to welcome him to the leadership team at this pivotal time for the Company.”

Dr. Mendelsohn mentioned, “On behalf of the Board and the entire Vivani team, I thank Brigid for her outstanding leadership and dedication. Her expertise and vision have been invaluable to our growth and success. This includes helping guide our company through a transformative period, including the successful completion of the merger of Nano Precision Medical and Second Sight Medical Products, and the advancement of our clinical and commercial strategy.”

Anthony Baldor brings over two decades of experience in financial leadership within the biotechnology industry. He has a strong background in fundraising, corporate strategy, and business development. Prior to joining Vivani, he served as CFO at Diakonos Oncology Corp., where he led both Series Seed and Series A financing rounds. Before that, he was Vice President of Corporate Strategy & Development at 4D Molecular Therapeutics, Inc., where he played an instrumental role in the company’s Series C fundraising, initial public offering, and strategic partnerships.

His earlier career includes roles at Jefferies Group LLC, BioInnovation Capital, LLC, RMI Partners, and Cequent Pharmaceuticals, Inc. Baldor holds an M.B.A. and a Master of Data Science from the University of California, Berkeley, as well as a B.A. from Vassar College. His appointment is expected to strengthen Vivani’s leadership team as the company advances its drug implant programs through clinical development.